Effect of recombinant human erythropoietin in a rat model of moderate chronic renal failure – focus on inflammation, oxidative Stress and function/renoprotection

Background/Aims: Chronic renal failure (CRF) patients develop anaemia, thus promoting cardiovascular complications, which seems to be favoured by the low kidney erythropoietin (EPO) production. The renal insufficiency degree might determine the moment to start recombinant human EPO (rhEPO) therapy....

Full description

Bibliographic Details
Main Author: Garrido, P. (author)
Other Authors: Reis, F. (author), Costa, E. (author), Almeida, A. (author), Parada, B. (author), Teixeira-Lemos, E. (author), Santos, P. (author), Alves, R. (author), Sereno, J. (author), Pinto, R. (author), Tavares, C.A. (author), Figueiredo, A. (author), Rocha-Pereira, P. (author), Belo, L. (author), Santos-Silva, A. (author), Teixeira, F. (author)
Format: article
Language:eng
Published: 2010
Subjects:
Moderate chronic renal failure
Erythropoietin treatment
Renoprotection
Proliferation
Inflammation
Oxidative stress
Online Access:http://hdl.handle.net/10400.14/3018
Country:Portugal
Oai:oai:repositorio.ucp.pt:10400.14/3018

Internet

http://hdl.handle.net/10400.14/3018

Similar Items